(Q38115721)

29 August 2017

title

Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs (English)

1 reference

29 August 2017

1 reference

1 reference

Philip N Patsalos

1

1 reference

29 August 2017

publication date

1 November 2013

1 reference

Clinical Pharmacokinetics

29 August 2017

published in

1 reference

29 August 2017

volume

52

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

927-966

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-013-0087-0

29 August 2017

exact match

0 references

cites work

Early identification of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The importance of drug interactions in epilepsy therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

New antiepileptic drugs: review on drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Clinically relevant drug interactions with antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Drug interactions involving the new second- and third-generation antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Methodologies used to identify and characterize interactions among antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetics and drug interactions of eslicarbazepine acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

A neuropharmacological evaluation of felbamate as a novel anticonvulsant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Long-term use of felbamate: clinical outcomes and effect of age and concomitant antiepileptic drug use on its clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lamotrigine pharmacokinetics in patients receiving felbamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetics of W-554 (ADD 03055) in epileptic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetic interaction studies between felbamate and vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Sodium valproate acutely inhibits lamotrigine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Effect of antiepileptic drug comedication on lamotrigine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Bidirectional interaction of valproate and lamotrigine in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Factors Influencing the Incidence of Lamotrigine-Related Skin Rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lamotrigine-associated rash: risk/benefit considerations in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

When thinking of lamotrigine and valproic acid, think "pharmacokinetically"!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Does lamotrigine influence valproate concentrations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Disabling tremor after lamotrigine with sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lamotrigine for generalised epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Vigabatrin and lamotrigine in refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Age and comedications influence levetiracetam pharmacokinetics in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Encephalopathy induced by levetiracetam added to valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Perampanel: as adjunctive therapy in patients with partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Multiple actions of the novel anticonvulsant drug topiramate in the rat subiculum in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Interaction of topiramate with carbamazepine: two case reports and a review of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Valproate-induced hyperammonemic encephalopathy in the presence of topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Topiramate enhances the risk of valproate-associated side effects in three children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Topiramate increases the risk of valproic acid-induced encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Effect of vigabatrin on the pharmacokinetics of carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Interaction between vigabatrin and phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Zonisamide enhances slow sodium inactivation in Myxicola

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Dose dependent enzyme induction by oxcarbazepine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

In Situ Metabolism of Levetiracetam in Blood of Patients with Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0087-0

Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.

21 January 2018

1 reference

12 December 2020

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

12 December 2020

Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy

1 reference

12 December 2020

Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy

1 reference

12 December 2020

Lamotrigine Plasma Concentrations in Children and Adults

1 reference

12 December 2020

Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy

1 reference

12 December 2020

Stiripentol kinetics in epilepsy: nonlinearity and interactions

1 reference

12 December 2020

The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response

1 reference

12 December 2020

Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy

1 reference

12 December 2020

Synergism with GABAergic drugs in refractory epilepsy

1 reference

12 December 2020

Interaction of lamotrigine with sodium valproate

1 reference

12 December 2020

Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up

1 reference

12 December 2020

Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.

1 reference

12 December 2020

Factors influencing serum topiramate concentrations in routine therapeutic drug monitoring in Korean adult patients with epilepsy

1 reference

12 December 2020

Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy

1 reference

12 December 2020

Adding valproate to lamotrigine: a study of their pharmacokinetic interaction

1 reference

12 December 2020

Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs

1 reference

12 December 2020

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

1 reference

12 December 2020

Effect of felbamate on plasma levels of carbamazepine and its metabolites

1 reference

12 December 2020

Effect of felbamate on phenytoin and carbamazepine serum concentrations

1 reference

12 December 2020

Lamotrigine and topiramate may be a useful combination

1 reference

12 December 2020

Acute effects of lamotrigine (BW430C) in persons with epilepsy

1 reference

12 December 2020

Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects

1 reference

12 December 2020

Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine

1 reference

12 December 2020

Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients

1 reference

12 December 2020

Population pharmacokinetics of felbamate in children

1 reference

12 December 2020

Effect of Felbamate on The Pharmacokinetics of Clonazepam

1 reference

12 December 2020

Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation

1 reference

12 December 2020

Effect of felbamate on the pharmacokinetics of lamotrigine

1 reference

12 December 2020

Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity

1 reference

12 December 2020

Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy

1 reference

12 December 2020

Lamotrigine drug interactions in a TDM material

1 reference

12 December 2020

Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine

1 reference

12 December 2020

Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy

1 reference

12 December 2020

Gabapentin interaction with felbamate

1 reference

12 December 2020

Effect of age and comedication on levetiracetam pharmacokinetics and tolerability

1 reference

12 December 2020

Discontinuation of phenytoin and carbamazepine in patients receiving felbamate

1 reference

12 December 2020

Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine

1 reference

12 December 2020

Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction

1 reference

12 December 2020

Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures

1 reference

12 December 2020

Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11 -epoxide

1 reference

12 December 2020

Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy

1 reference

12 December 2020

Lamotrigine in infantile spasms

1 reference

12 December 2020

Felbamate Increases Phenytoin but Decreases Carbamazepine Concentrations

1 reference

12 December 2020

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

1 reference

12 December 2020

Effect of felbamate on carbamazepine and its major metabolites

1 reference

12 December 2020

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study

1 reference

12 December 2020

Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine

1 reference

12 December 2020

Effects of felbamate on the pharmacokinetics of phenobarbital

1 reference

12 December 2020

The effect of felbamate on valproic acid disposition

1 reference

12 December 2020

Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?

1 reference

12 December 2020

Rufinamide in children with refractory epilepsy: pharmacokinetics, efficacy, and safety

1 reference

12 December 2020

Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy

1 reference

12 December 2020

Lacosamide-induced valproic acid toxicity

1 reference

12 December 2020

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

1 reference

12 December 2020

Potential pharmacokinetic interaction between felbamate and phenobarbital

1 reference

12 December 2020

Calcium channel alpha(2)delta subunits-structure and Gabapentin binding

1 reference

12 December 2020

Lamotrigine as an add-on drug in typical absence seizures

1 reference

12 December 2020

Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group

1 reference

12 December 2020

Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications

1 reference

12 December 2020

Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses

1 reference

12 December 2020

Pharmacokinetic Interactions Between Lamotrigine and Other Antiepileptic Drugs in Children with Intractable Epilepsy

1 reference

12 December 2020

A study of topiramate pharmacokinetics and tolerability in children with epilepsy

1 reference

12 December 2020

10.1007/S40262-013-0087-0

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1032722207

0 references

1 reference